FY2025 EPS Estimates for Novavax Lifted by Zacks Research

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Analysts at Zacks Research lifted their FY2025 earnings estimates for Novavax in a research report issued to clients and investors on Tuesday, January 28th. Zacks Research analyst S. Ganoria now expects that the biopharmaceutical company will earn ($0.72) per share for the year, up from their previous estimate of ($0.77). The consensus estimate for Novavax's current full-year earnings is ($1.31) per share.

A number of other analysts also recently commented on the company. B. Riley reaffirmed a "buy" rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, October 16th. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Novavax currently has a consensus rating of "Hold" and an average price target of $17.83.

Novavax Stock Up 0.2 %

Novavax stock traded up $0.02 during midday trading on Friday, hitting $8.45. 3,812,978 shares of the stock were exchanged, compared to its average volume of 4,796,931. Novavax has a 52-week low of $3.53 and a 52-week high of $23.86. The business's 50-day moving average price is $8.83 and its 200-day moving average price is $10.71. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.74, a price-to-earnings-growth ratio of 66.26 and a beta of 2.14.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. During the same period in the previous year, the company posted ($1.26) earnings per share. The company's quarterly revenue was down 54.8% compared to the same quarter last year.

Hedge Funds Weigh In On Novavax

A number of large investors have recently added to or reduced their stakes in NVAX. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 1,598 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Novavax by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after acquiring an additional 1,664 shares during the period. Victory Capital Management Inc. grew its position in Novavax by 12.0% during the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 2,072 shares during the last quarter. Creative Planning increased its stake in Novavax by 12.5% in the 2nd quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company's stock worth $306,000 after purchasing an additional 2,692 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Novavax by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 3,174 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company's stock.

Insider Activity

In other news, Director Rachel K. King sold 4,150 shares of the company's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This represents a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James F. Young sold 4,600 shares of the firm's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total value of $39,008.00. Following the transaction, the director now directly owns 57,160 shares in the company, valued at approximately $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,150 shares of company stock worth $119,641. 1.00% of the stock is owned by company insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.